SCHEMBL4582832

SCHEMBL4582832

[CH2]c1ccc(-c2cnc(N3CCNCC3)nc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.49
ALDH1A1 P00352 2/20 0.49
KDM4E B2RXH2 1/20 0.49
CHRNB2 P17787 2/20 0.42
CHRNA4 P43681 2/20 0.42
ROCK2 O75116 2/20 0.42
MAPT P10636 1/20 0.42
FEN1 P39748 1/20 0.42
INPPL1 O15357 1/20 0.42
ACVR1 Q04771 2/20 0.41
BMPR1A P36894 1/20 0.41
ACVR1B P36896 1/20 0.41
ACVRL1 P37023 1/20 0.41
GPR119 Q8TDV5 1/20 0.40
KCNH2 Q12809 1/20 0.40
CACNA1C Q13936 1/20 0.40
ASIC3 Q9UHC3 1/20 0.40
HRH1 P35367 1/20 0.39
ADRB1 P08588 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9400849 0.83 HTR3A (0.54) TAAR1ALDH1A1KDM4EINPPL1ADRB1
SCHEMBL6787637 0.83 HTR7 (0.54) TAAR1ALDH1A1KDM4EFEN1ACVR1
SCHEMBL4582837 0.83 HTR1A (0.54) TAAR1ALDH1A1KDM4ECHRNB2CHRNA4
SCHEMBL9400977 0.83 TAAR1 (0.64) TAAR1ALDH1A1KDM4EACVR1BMPR1A
SCHEMBL25255051 0.82 ALDH1A1 (0.59) TAAR1ALDH1A1KDM4ECHRNB2CHRNA4
Hydrochloric Acid SCHEMBL20293632 0.82 HTR7 (0.52) TAAR1ALDH1A1KDM4EFEN1ACVR1
Hydrochloric Acid SCHEMBL20293649 0.82 HTR3A (0.52) TAAR1ALDH1A1KDM4EINPPL1ADRB1
Hydrochloric Acid SCHEMBL6786943 0.82 HTR7 (0.52) TAAR1ALDH1A1KDM4EFEN1ACVR1
SCHEMBL4582030 0.81 TAAR1 (0.48) TAAR1ALDH1A1KDM4EMAPTFEN1
SCHEMBL6785572 0.81 HRH3 (0.49) TAAR1ALDH1A1KDM4EHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2139483-B9 COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER EXELIXIS INC (US) 2014-05-21 EP disclosed
US-8362017-B2 N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening EXELIXIS, INC. (US) 2013-01-29 US disclosed
US-20080096892-A1 C-Kit Modulators And Methods Of Use EXELIXIS, INC. (US) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096892-A1 C-Kit Modulators And Methods Of Use KIT, PRKCH, PRKCB TAAR1 4080/4885ALDH1A1 2190/4885KDM4E 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.